Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Almac Co. Ltd. (354320:KRX), powered by AI.
Almac Co. Ltd. is currently trading at ₩53,700. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Almac Co. Ltd. on Alpha Lenz.
Almac Co. Ltd.'s P/E ratio is -261.7.
“Almac Co. Ltd. trades at a P/E of -261.7 (undervalued) with modest ROE of -0.9%.”
Ask for details →Almac Co. Ltd. is a prominent entity in the healthcare and pharmaceutical industry, primarily engaged in the provision of advanced drug development services. The company is dedicated to innovating and streamlining the complex processes involved in bringing therapeutic solutions from conceptual stages to market availability. With core competencies in research, development, and manufacturing, Almac Co. Ltd. significantly impacts both the biotechnology and pharmaceutical sectors. This company is renowned for its comprehensive service portfolio, which includes clinical trial management, bioscience research, global drug supply management, and specialized analytics. Almac Co. Ltd. operates a worldwide network, ensuring seamless integration and service delivery across various continents, thereby facilitating global healthcare advancement. Based in Craigavon, Northern Ireland, its extensive collaboration with researchers, scientists, and pharmaceutical companies highlights its pivotal role in expediting drug development cycles while maintaining stringent compliance with regulatory standards in multiple jurisdictions. As a result, Almac Co. Ltd. is crucial in reducing healthcare costs and improving medication accessibility on a global scale.
“Almac Co. Ltd. trades at a P/E of -261.7 (undervalued) with modest ROE of -0.9%.”
Ask for details →Almac Co. Ltd. (ticker: 354320) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $343.2B.
The current price is ₩53,700 with a P/E ratio of -261.68x and P/B of 2.28x.
ROE is -0.90% and operating margin is 3.31%. Annual revenue is $187.8B.